J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
And AbbVie and Genmab scoop their ASH presentation with new data.
But Enhertu is coming.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The restructured biotech’s new lead project enters phase 1.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
